Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

November 13, 2019

CRISPR-edited T-cells Safely, Effectively Target Cancer Cells in Myeloma Patients, Early Phase 1 Data Suggests

News

A new approach using genetically modified T-cells — via CRISPR-Cas9 gene editing technology — safely and effectively targets cancer cells in patients with advanced multiple myeloma, preliminary data from ... Read more

November 6, 2019November 6, 2019

Use of Darzalez and Xpovio Expected to Increase Due to New Approvals, Spherix Survey Shows

News

U.S. blood cancer specialists are aware of recent approvals for multiple myeloma patients and expect to increase their use of Darzalex (daratumumab) as first-line combination therapy, as well as Xpovio ... Read more

October 25, 2019

CHMP Recommends Darzalex Triple Combo for Some Newly Diagnosed Multiple Myeloma Patients in EU

News

The European Medicines Agency (EMA) has recommended that Darzalex (daratumumab) be approved in Europe, in combination with Revlimid (lenalidomide) and dexamethasone, as a first-line treatment for multiple myeloma patients who are ineligible for autologous ... Read more

September 13, 2019

Researchers Identify Promising Target for CAR T-cell Therapy in Myeloma

News

Designing CAR T-cells to specifically target GPRC5D — a protein appreciably present on the surface of myeloma cells — may be a safe and effective therapy against multiple myeloma, a ... Read more

August 23, 2019

Kalytera’s Cannabidiol Prevents Graft-Versus-Host-Disease After Bone Marrow Transplant, Data Show

News

Kalytera’s cannabidiol (CBD) compound efficiently prevents graft-versus-host disease (GVHD) in patients receiving bone marrow transplants from matched unrelated donors, interim data from a Phase 2 study show. Considering the study’s ... Read more

December 5, 2018

Researchers Identify 3 Genetic Alterations Associated with Higher Risk of Myeloma in African-Americans

News

Researchers have identified three genetic alterations associated with the known twofold to threefold risk of multiple myeloma among African-Americans. The study, “Differences in genomic abnormalities among African individuals with monoclonal ... Read more

August 17, 2018

BL-8040 Speeds Collection of Stem Cells for Transplant in Myeloma Patients, Phase 3 Data Suggest

News

Adding BioLineRx‘s BL-8040 to standard treatment greatly improves the mobilization of blood stem cells to be collected for stem cell transplants in patients with multiple myeloma, according to interim ... Read more

July 2, 2018July 2, 2018

Advanced Blood Sample Analysis Could Be Better Than Bone Marrow Biopsies, Study Shows

News

Genetic analysis of multiple myeloma DNA from two different sources present in blood samples provides researchers equally relevant cancer information as more invasive bone marrow biopsies, a study shows. ... Read more

May 21, 2018

MS Therapy May Ease Painful Side Effect of Velcade Treatment in Myeloma Patients, Study Says

News

A multiple sclerosis (MS) treatment reduced a common painful side effect of Velcade (bortezomib) in a mouse model, suggesting that it might help myeloma patients complete their treatment and ... Read more

May 11, 2018

FDA Approves Darzalex Combo Therapy for Certain Newly Diagnosed Patients

News

The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with standard therapy for the treatment of patients with newly-diagnosed multiple myeloma who are not eligible for stem ... Read more

Pin It on Pinterest